ELEVIDYS UPDATE

ELEVIDYS UPDATE

Breaking News: Sarepta to resume shipments of ELEVIDYS for ambulatory individuals with Duchenne 07/28/25 5:09 PM EDT We are pleased to report that the US FDA has recommended that Sarepta […]

Satellos reports data from their Phase 1b study

Satellos Biosciences announced their Phase 1b results from their open-label study with SAT-3247, which aims to improve muscle regeneration in Duchenne.  SAT-3247 was safe and well-tolerated in 5 individuals with […]